Screener
Aurinia Pharmaceuticals AUPH Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Share-based compensation | 1,973 | 2,031 |
| Amortization and depreciation | 9,650 | 9,720 |
| Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability | (977) | 9,265 |
| Net amortization of premiums and discounts on investments | (4,200) | (5,219) |
| Other, net | (2,082) | 4,132 |
| Net changes in operating assets and liabilities: | ||
| Accounts receivable, net | 316 | (3,547) |
| Inventory | 539 | (7,275) |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Aurinia Pharmaceuticals (AUPH) reported accretion (amortization) of discounts and premiums, investments of $1.88M in Q2 2026.
- How has Aurinia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Aurinia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 26.6% year-over-year, from $2.56M to $1.88M.
- What is the long-term trend for Aurinia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 98.2% compound annual growth rate (CAGR), from -$660K to $10.18M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This reflects the periodic adjustment of the carrying value of investment securities to their face value over time. It represents the non-cash recognition of interest income or expense related to the purchase of debt instruments at prices other than par. This metric is essential for understanding the true yield and effective interest earned on the company's investment portfolio.
Ask your AI about Aurinia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude